Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 29:12:892323.
doi: 10.3389/fcimb.2022.892323. eCollection 2022.

Integrins as Therapeutic Targets for SARS-CoV-2

Timothy E Gressett  1   2   3 , Danielle Nader  4 , Juan Pablo Robles  5 , Tione Buranda  6 , Steven W Kerrigan  4 , Gregory Bix  1   2   3
Affiliations

Integrins as Therapeutic Targets for SARS-CoV-2

Timothy E Gressett et al. Front Cell Infect Microbiol. .
No abstract available

Keywords: ATN-161; RGD; SARS-CoV-2; cilengitide; integrins; therapeutic.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Schematic diagram of SARS-CoV-2 interaction with proposed receptors and therapeutics. Integrins α5β1 and αVβ3 have been reported to bind the RGD motif of the spike protein. Peptide compounds ATN-161 and Cilengitide target these integrins and have displayed efficacy in reducing SARS-CoV-2 infection and spike-mediated endothelial dysfunction. (B) Multiple sequence alignment using EMBL-EBI Clustal Omega tool between spike proteins of the SARS-CoV-2 Wuhan wild type, and variants of concern Alpha, Beta, Gamma, Delta, and Omicron. The symbols (*) and (.) indicate conserved and weakly similar amino acids, respectively. The RGD motif is highlighted in yellow, where it is preserved across all major variants.
See this image and copyright information in PMC

References

    1. Aguirre C., Meca-Lallana V., Barrios-Blandino A., Del Río B., Vivancos J. (2020). Covid-19 in a Patient With Multiple Sclerosis Treated With Natalizumab: May the Blockade of Integrins Have a Protective Role? Mult Scler. Relat. Disord. 44, 102250. doi: 10.1016/j.msard.2020.102250 - DOI - PMC - PubMed
    1. Amruta N., Engler-Chiurazzi E. B., Murray-Brown I. C., Gressett T. E., Biose I. J., Chastain W. H., et al. . (2021). In Vivo Protection From SARS-CoV-2 Infection by ATN-161 in K18-Hace2 Transgenic Mice. Life Sci. 284, 119881. doi: 10.1016/j.lfs.2021.119881 - DOI - PMC - PubMed
    1. Babaesfahani A., Khanna N. R., Kuns B. (2022). “Natalizumab,” in StatPearls (Treasure Island (FL: StatPearls Publishing; ). - PubMed
    1. Beaudoin C. A., Hamaia S. W., Huang C. L.-H., Blundell T. L., Jackson A. P. (2021). Can the SARS-CoV-2 Spike Protein Bind Integrins Independent of the RGD Sequence? Front. Cell. Infect. Microbiol. 11, 1116. doi: 10.3389/fcimb.2021.765300 - DOI - PMC - PubMed
    1. Beddingfield B. J., Iwanaga N., Chapagain P. P., Zheng W., Roy C. J., Hu T. Y., et al. . (2021). The Integrin Binding Peptide, ATN-161, As a Novel Therapy for SARS-CoV-2 Infection. JACC Basic Transl. Sci. 6 (1), 1–8. doi: 10.1016/j.jacbts.2020.10.003 - DOI - PMC - PubMed